Large Molecule Bioanalysis for Every Stage of Drug Development

KCAS Bio is an industry-leading expert in large molecule bioanalysis, specializing in quantifying proteins, antibodies, and other large molecule modalities in various fluids and tissues from early discovery through clinical phases. Our highly experienced scientists leverage state-of-the-art technologies, including ligand binding platforms (LBA), Hybrid LC-MS approaches, flow cytometry, and molecular technologies, to support all aspects of large molecule bioanalysis.

LBA or Hybrid LC-MS

It depends. At KCAS Bio, we are committed to evaluating the relative merits of available technologies to determine the optimal solution. With extensive expertise across all bioanalytical methodologies required for large molecule bioanalysis—combined with our state-of-the-art instrumentation—we ensure a tailored, science-driven approach to best meet our clients’ needs. Our integrated service lines enable seamless pivoting between these complementary technologies to ensure the best data-driven approach for our clients.